Showing results 1 to 20 of 40
next >
| Issue Date | Title | Author(s) |
| 9-Jul-2021 | Afatinib in EGFR TKI-Naive Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies | Passaro, Antonio; de Marinis, Filippo; Tu, Hai-Yan; Laktionov, Konstantin K.; Feng, Jifeng; Poltoratskiy, Artem; Zhao, Jun; Tan, Eng Huat; Gottfried, Maya; Lee, Victor; Kowalski, Dariusz; Yang, Cheng Ta; Srinivasa, B. J.; Clementi, Laura; Jalikop, Tejaswini; Huang, Dennis Chin Lun; Cseh, Agnieszka; Park, Keunchil; Wu, Yi-Long |
| 15-Apr-2020 | Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study | Lu, Chang; Dong, Xiao-Rong; Zhao, Jun; Zhang, Xu-Chao; Chen, Hua-Jun; Zhou, Qing; Tu, Hai-Yan; Ai, Xing-Hao; Chen, Xiao-Feng; An, Gai-Li; Bai, Jun; Shan, Jin-Lu; Wang, Yi-Na; Yang, Shuan-Ying; Liu, Xiang; Zhuang, Wu; Wu, Hui-Ta; Zhu, Bo; Xia, Xue-Feng; Chen, Rong-Rong; Gu, De-Jian; Xu, Hua-Min; Wu, Yi-Long; Yang, Jin-Ji |
| Feb-2022 | Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm plus non-small-cell lung cancer | Zhao, Jun; Bai, Hua; Wang, Xin; Wang, Yuyan; Duan, Jianchun; Chen, Hanxiao; Xue, Zhiyi; Tian, Yahui; Cseh, Agnieszka; Huang, Dennis Chin-Lun; Wu, Yi-Long; Wang, Jie |
| Mar-2021 | Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer | Ni, Jun; Huang, Miao; Zhang, Li; Wu, Nan; Bai, Chun-Xue; Chen, Liang-An; Liang, Jun; Liu, Qian; Wang, Jie; Wu, Yi-Long; Zhang, Feng-Chun; Zhang, Shu-Yang; Chen, Chun; Chen, Jun; Fang, Wen-Tao; Gao, Shu-Geng; Hu, Jian; Jiang, Tao; Li, Shan-Qing; Li, He-Cheng; Liao, Yong-De; Liu, Yang; Liu, De-Ruo; Liu, Hong-Xu; Liu, Jian-Yang; Liu, Lun-Xu; Wang, Meng-Zhao; Wang, Chang-Li; Yang, Fan; Yang, Yue; Zhang, Lan-Jun; Zhi, Xiu-Yi; Zhong, Wen-Zhao; Guan, Yu-Zhou; Guo, Xiao-Xiao; He, Chun-Xia; Li, Shao-Lei; Li, Yue; Liang, Nai-Xin; Lu, Fang-Liang; Lv, Chao; Lv, Wei; Si, Xiao-Yan; Tan, Feng-Wei; Wang, Han-Ping; Wang, Jiang-Shan; Yan, Shi; Yang, Hua-Xia; Zhu, Hui-Juan; Zhuang, Jun-Ling; Zhuo, Ming-Lei |
| 2019 | Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients | Zhang, Xu-Chao; Wang, Jun; Shao, Guo-Guang; Wang, Qun; Qu, Xiaotao; Wang, Bo; Moy, Christopher; Fan, Yue; Albertyn, Zayed; Huang, Xiayu; Zhang, Jingyu; Qiu, Yang; Platero, Suso; Lorenzi, Matthew V.; Zudaire, Enrique; Yang, Jennifer; Cheng, Ying; Xu, Lin; Wu, Yi-Long |
| 2018 | A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel | Wu, Yi-Long; Wang, Chang-Li; Liao, Mei-Lin; Guan, Zhong-Zhen; Gao, Chen-Yan; Lu, Shun; Zhao, Ming-Fang; Wang, Jie; Liu, Xiao-Qing; Yang, Jin-Ji; Liang, Jun; Mao, Wei-Min; Han, Bao-Hui; Zhang, Xu-Chao; Song, Yong; Feng, Ji-Feng; Ma, Sheng-Lin; Wu, Gang; Zhou, Cai-Cun; Chen, Ke-Neng; Cheng, Ying; He, Yong; Chen, Chun; Wang, Qun; Lin, Ji-Zhen; Zhu, Bo; Liu, Yun-Peng; Hu, Yi; Qiao, Gui-Bin; Zhou, Qing; Song, Qi-Bin; Wu, Nan; Wu, Lin; Huang, Cheng; Fu, Xiao-Long; Xiong, Jian-Ping; Hu, Jie; Hu, Cheng-Ping; Chang, Jian-Hua; Zhao, Qiong; Zhao, Jun; Zhou, |
| 2017 | A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel | Wu, Yi-Long; Wang, Chang-Li; Sun, Yan; Liao, Mei-Lin; Guan, Zhong-Zhen; Yang, Zhi-Min; Zhou, Qing-Hua; Lu, Shun; Cheng, Ying; Liu, Xiao-Qing; Zhang, Xu-Chao; Zhou, Caicun; Wang, Jie; Zhou, Qing; Song, Yong; Han, Bao-Hui; Ma, Zhi-Yong; Yang, Fan; Wang, Qun; Chuai, Shao-Kun; Shao, Yang; He, Wei; Zhu, Guanshan; Xiong, Lei; Wang, Jian-Jun; Chen, Ke-Neng; Zhang, Li; Mao, Wei-Min; Ma, Sheng-Lin; Feng, Ji-Feng; Yang, Xue-Ning; Xu, Lin; Chen, Gang; Zhao, Jian; Song, Qi-Bin; Shen-Tu, Yang; Qiao, Gui-Bin; Yu, Ding; Yu, Shi-Ying; Hu, Yi; Chen, Ming; Chen, Go |
| Dec-2024 | Consensus on the lung cancer management after third-generation EGFR-TKI resistance | Zhou, Qing; Zhao, Hongyun; Lu, Shun; Cheng, Ying; Liu, Ying; Zhao, Mingfang; Yu, Zhuang; Hu, Chengping; Zhang, Li; Yang, Fan; Zhao, Jun; Guo, Renhua; Ma, Rui; Du, Yingying; Dong, Xiaorong; Cui, Jiuwei; Tan, Daniel S. W.; Ahn, Myung-Ju; Tsuboi, Masahiro; Liu, Si-Yang Maggie; Mok, Tony S.; Wu, Yi-Long |
| 20-May-2021 | CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer. | Wu, Yi-Long; Zhong, Wenzhao; Chen, Ke-Neng; Chen, Chun; Yang, Fan; Yang, Xue-Ning; Gu, Chundong; Mao, Weimin; Wang, Qun; Qiao, Gui-Bin; Cheng, Ying; Xu, Lin; Wang, Changli; Chen, Mingwei; Yan, Hong-Hong; Liao, Ri-qiang; Zhang, Xuchao; Yang, Jinji; Liu, Si-yang; Zhou, Qing |
| 20-May-2020 | CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. | Wu, Yi-Long; Zhong, Wenzhao; Wang, Qun; Mao, Weimin; Xu, Song-Tao; Wu, Lin; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhidong; Xu, Shun; Yang, Jin-Ji; Yan, Hong-Hong; Yang, Xue-Ning; Liu, Si-yang; Zhou, Qing |
| Jan-2020 | Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study | Zhang, Jia-Tao; Li, Ye; Yan, Li-Xu; Zhu, Zheng-Fei; Dong, Xiao-Rong; Chu, Qian; Wu, Lin; Zhang, Hong-Mei; Xu, Chun-Wei; Lin, Gen; Yu, Zong-Yang; Hu, Jie; Zhu, Bo; Wang, Hui-Juan; Yang, Fan; Song, Zheng-Bo; Han, Zheng-Bo; Li, Meng-Xia; Lin, Jie; Wu, Yi-Long; Wang, Jin-Liang; Zhong, Wen-Zhao |
| 2011 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Zhou, Caicun; Wu, Yi-Long; Chen, Gongyan; Feng, Jifeng; Liu, Xiao-Qing; Wang, Changli; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Chengping; Hu, Chunhong; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu; Ma, Jun; Zhang, Li; You, Changxuan |
| 2019 | Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study | Zhong, Wen-Zhao; Chen, Ke-Neng; Chen, Chun; Gu, Chun-Dong; Wang, Jun; Yang, Xue-Ning; Mao, Wei-Min; Wang, Qun; Qiao, Gui-Bin; Cheng, Ying; Xu, Lin; Wang, Chang-Li; Chen, Ming-Wei; Kang, Xiaozheng; Yan, Wanpu; Yan, Hong-Hong; Liao, Ri-Qiang; Yang, Jin-Ji; Zhang, Xu-Chao; Zhou, Qing; Wu, Yi-Long |
| 2017 | Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses | Mok, Tony S. K.; Kim, Sang-We; Wu, Yi-Long; Nakagawa, Kazuhiko; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Shi, Xiaojin; Rukazenkov, Yuri; Haddad, Vincent; Thress, Kenneth S.; Soria, Jean-Charles |
| 2015 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial | Soria, Jean-Charles; Wu, Yi-Long; Nakagawa, Kazuhiko; Kim, Sang-We; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Lee, Dae Ho; Liu, Yunpeng; Yoh, Kiyotaka; Zhou, Jian-Ying; Shi, Xiaojin; Webster, Alan; Jiang, Haiyi; Mok, Tony S. K. |
| 2018 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study | Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yan, Hong-Hong; Yang, Xue-Ning; Zhou, Qing; Wu, Yi-Long |
| 1-Mar-2021 | Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial | Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Wei, Yu-Cheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Sheng-Xiang; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yang, Jin-Ji; Yan, Hong-Hong; Yang, Xue-Ning; Liu, Si-Yang; Zhou, Qing; Wu, Yi-Long |
| 2015 | Gefitinib/Chemotherapy vs Chemotherapy in EGFR Mutation-Positive NSCLC Resistant to First-Line Gefitinib: IMPRESS T790M Subgroup Analysis | Soria, Jean-Charles; Kim, Sang-We; Wu, Yi-Long; Nakagawa, Kazuhiko; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Shi, Xiaojin; Taylor, Rosemary; Jiang, Haiyi; Thress, Kenneth; Mok, Tony |
| Oct-2020 | GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiothera | Zhou, Qing; Chen, Ming; Wu, Gang; Chang, Jian-Hua; Jiang, Ou; Cui, Jiu-Wei; Han, Guang; Lin, Qin; Fang, Jian; Chen, Gong-Yan; Wu, Yi-Long |
| 8-Nov-2021 | Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes | Liu, Si-Yang; Bao, Hua; Wang, Qun; Mao, Wei-Min; Chen, Yedan; Tong, Xiaoling; Xu, Song-Tao; Wu, Lin; Wei, Yu-Cheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Sheng-Xiang; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yan, Hong-Hong; Dong, Song; Zhang, Xu-Chao; Su, Jian; Yang, Jin-Ji; Yang, Xue-Ning; Zhou, Qing; Wu, Xue; Shao, Yang; Zhong, Wen-Zhao; Wu, Yi-Long |
